Curated News
By: NewsRamp Editorial Staff
September 28, 2026
Viromed Advances Cold Plasma Products, Confirms 2026 Guidance
TLDR
- Viromed's equity jumped 43.9% to EUR 9.5 million with full-year revenue growth expected, offering investors a strong growth opportunity.
- Viromed advanced cold plasma products, secured MDR approval for ViroCAP med, and planned acquisition of relyon plasma GmbH to drive future sales.
- Viromed's cold plasma technology and PulmoPlas study aim to improve medical treatments, potentially benefiting patients and advancing healthcare worldwide.
- Viromed's half-year report shows revenue of EUR 2.5 million, a EUR 550,000 research grant, and the start of ViroCAP med sales in July 2026.
Impact - Why it Matters
This news matters because Viromed's progress in cold plasma technology could lead to innovative medical treatments, particularly with PulmoPlas® and ViroCAP® med, offering new options for patients and healthcare providers. The successful MDR certification of ViroCAP® med and the exclusive veterinary partnership signal growing market acceptance, while the strong equity ratio and revenue growth indicate financial stability and potential for investors. As cold plasma gains scientific validation, it may revolutionize wound care and respiratory therapies, impacting a broad range of medical fields.
Summary
Viromed Medical AG, a German medical technology company and pioneer of cold plasma technology, has published its half-year report for 2026, revealing progress in product development, strategic partnerships, and financial performance. In the first half of 2026, the company advanced its product pipeline, expanded sales partnerships, and focused on the planned acquisition of relyon plasma GmbH. CEO Uwe Perbandt highlighted the successful continuation of product development and preclinical research, noting that upcoming publication of study results in a renowned scientific journal will strengthen the scientific evidence for cold plasma technology. Key operational milestones included continued preclinical development of PulmoPlas®, initiation of OEM production of ViroCAP® for HELLMUT RUCK GmbH, and an exclusive sales partnership with NEBU-TEC for veterinary applications of PulmoPlas®. Viromed also completed the conformity assessment for ViroCAP® med as a Class IIa medical device under EU MDR, receiving approval in July 2026, which allows sales to begin. Additionally, the company secured a EUR 550,000 research allowance for cold plasma R&D.
Financially, Viromed reported consolidated revenue of EUR 2.5 million for H1 2026, up slightly from EUR 2.4 million in H1 2025, while net loss widened to EUR 1.1 million from EUR 0.8 million, attributed to expenses for the PulmoPlas® study and ViroCAP® med launch. Equity increased by 43.9% to EUR 9.5 million, raising the equity ratio to 67.6% from 39.9%. The company financed itself primarily through a EUR 2.7 million loan from Perbamed Invest GmbH, approved by the supervisory board and tax advisor. For the full year 2026, Viromed expects significant revenue and net income growth, confirming its adjusted guidance. The half-year financial statements are available on the website.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Viromed Advances Cold Plasma Products, Confirms 2026 Guidance
